[{"orgOrder":0,"company":"Synaffix","sponsor":"Shanghai Miracogen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Synaffix announces expansion of license agreement with Shanghai Miracogen Inc. to a second ADC candidate","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"NETHERLANDS","productType":"Undisclosed","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Antibody drug conjugate linker","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Synaffix","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Synaffix \/ Shanghai Miracogen","highestDevelopmentStatusID":"1","companyTruncated":"Synaffix \/ Shanghai Miracogen"},{"orgOrder":0,"company":"Synaffix","sponsor":"ADC Therapeutics","pharmaFlowCategory":"D","amount":"$54.0 million","upfrontCash":"Undisclosed","newsHeadline":"Synaffix Announces Expansion of Collaboration with ADC Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"Antibody-drug conjugates","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Synaffix","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Synaffix \/ ADC Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Synaffix \/ ADC Therapeutics"},{"orgOrder":0,"company":"Synaffix","sponsor":"ProfoundBio","pharmaFlowCategory":"D","amount":"$246.0 million","upfrontCash":"Undisclosed","newsHeadline":"Synaffix Announces Deal with ProfoundBio Worth up to $246 Million Providing Access to Multiple Novel Linker-Payload Technologies","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Licensing Agreement","leadProduct":"PRO1184","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Synaffix","amount2":0.25,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.25,"dosageForm":"","sponsorNew":"Synaffix \/ Synaffix","highestDevelopmentStatusID":"7","companyTruncated":"Synaffix \/ Synaffix"},{"orgOrder":0,"company":"Synaffix","sponsor":"Kyowa Kirin","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Kyowa Kirin Taps Synaffix ADC Technology to Expand Its Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Antibody-drug Conjugate Therapeutic","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Synaffix","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Synaffix \/ Kyowa Kirin","highestDevelopmentStatusID":"4","companyTruncated":"Synaffix \/ Kyowa Kirin"},{"orgOrder":0,"company":"Synaffix","sponsor":"Mersana Therapeutics","pharmaFlowCategory":"D","amount":"$1,000.0 million","upfrontCash":"Undisclosed","newsHeadline":"Synaffix Announces $1 Billion Deal Expansion with Mersana","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Licensing Agreement","leadProduct":"XMT-1592","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Synaffix","amount2":1,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1,"dosageForm":"Intravenous Infusion","sponsorNew":"Synaffix \/ Mersana Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Synaffix \/ Mersana Therapeutics"},{"orgOrder":0,"company":"Synaffix","sponsor":"Genmab","pharmaFlowCategory":"D","amount":"$419.5 million","upfrontCash":"$4.5 million","newsHeadline":"Genmab and Synaffix Enter into License Agreement for ADC Technology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Antibody-drug Conjugates","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Synaffix","amount2":0.41999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.41999999999999998,"dosageForm":"","sponsorNew":"Synaffix \/ Genmab","highestDevelopmentStatusID":"4","companyTruncated":"Synaffix \/ Genmab"},{"orgOrder":0,"company":"Synaffix","sponsor":"Kyowa Kirin","pharmaFlowCategory":"D","amount":"$176.0 million","upfrontCash":"$5.0 million","newsHeadline":"Kyowa Kirin Expands License Agreement with Synaffix and Takes Exclusive Target Rights Based on Latest Positive ADC Data","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Antibody-drug Conjugate Therapeutic","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Synaffix","amount2":0.17999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.17999999999999999,"dosageForm":"","sponsorNew":"Synaffix \/ Kyowa Kirin Co.","highestDevelopmentStatusID":"4","companyTruncated":"Synaffix \/ Kyowa Kirin Co."},{"orgOrder":0,"company":"Synaffix","sponsor":"Emergence Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$360.0 million","newsHeadline":"Emergence Therapeutics Licenses Synaffix ADC Technology Platform in $360M Deal","therapeuticArea":"Technology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Antibody-drug Conjugate","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Preclinical","graph3":"Synaffix","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Synaffix \/ Emergence","highestDevelopmentStatusID":"4","companyTruncated":"Synaffix \/ Emergence"},{"orgOrder":0,"company":"Synaffix","sponsor":"Amgen Inc","pharmaFlowCategory":"D","amount":"$2,000.0 million","upfrontCash":"Undisclosed","newsHeadline":"Synaffix Enters License Agreement with Amgen to Build Next Generation ADCs","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Antibody-drug Conjugate-based Therapy","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Preclinical","graph3":"Synaffix","amount2":2,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":2,"dosageForm":"","sponsorNew":"Synaffix \/ Amgen Inc","highestDevelopmentStatusID":"4","companyTruncated":"Synaffix \/ Amgen Inc"},{"orgOrder":0,"company":"Synaffix","sponsor":"Hummingbird Bioscience","pharmaFlowCategory":"D","amount":"$150.0 million","upfrontCash":"Undisclosed","newsHeadline":"Hummingbird Bioscience and Synaffix Enter License Agreement to Develop a Next Generation Antibody Drug Conjugate (ADC) Program","therapeuticArea":"Technology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Antibody-drug Conjugate-based Therapy","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Preclinical","graph3":"Synaffix","amount2":0.14999999999999999,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0.14999999999999999,"dosageForm":"","sponsorNew":"Synaffix \/ Hummingbird Bioscience","highestDevelopmentStatusID":"4","companyTruncated":"Synaffix \/ Hummingbird Bioscience"},{"orgOrder":0,"company":"Synaffix","sponsor":"Chong Kun Dang Pharm","pharmaFlowCategory":"D","amount":"$132.0 million","upfrontCash":"Undisclosed","newsHeadline":"Chong Kun Dang Pharm Licenses Synaffix ADC Technology, Adds Novel ADC Candidate to Oncology Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Antibody-drug Conjugate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Synaffix","amount2":0.13,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.13,"dosageForm":"","sponsorNew":"Synaffix \/ Chong Kun Dang Pharm","highestDevelopmentStatusID":"2","companyTruncated":"Synaffix \/ Chong Kun Dang Pharm"},{"orgOrder":0,"company":"Synaffix","sponsor":"MacroGenics","pharmaFlowCategory":"D","amount":"$586.0 million","upfrontCash":"Undisclosed","newsHeadline":"Synaffix Inks $586m Deal with MacroGenics to Enable Next Generation ADCs","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Agreement","leadProduct":"Antibody-drug Conjugate","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Preclinical","graph3":"Synaffix","amount2":0.58999999999999997,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0.58999999999999997,"dosageForm":"","sponsorNew":"Synaffix \/ MacroGenics","highestDevelopmentStatusID":"4","companyTruncated":"Synaffix \/ MacroGenics"},{"orgOrder":0,"company":"Synaffix","sponsor":"MacroGenics","pharmaFlowCategory":"D","amount":"$2,200.0 million","upfrontCash":"Undisclosed","newsHeadline":"Synaffix Announces Expansion of ADC Collaboration with MacroGenics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Antibody-drug Conjugate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Synaffix","amount2":2.2000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":2.2000000000000002,"dosageForm":"","sponsorNew":"Synaffix \/ MacroGenics","highestDevelopmentStatusID":"2","companyTruncated":"Synaffix \/ MacroGenics"},{"orgOrder":0,"company":"Synaffix","sponsor":"ABL Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ABL Bio Taps into Synaffix ADC Technology to Accelerate Development of Bispecific ADC Products","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Synaffix","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Synaffix \/ ABL Bio","highestDevelopmentStatusID":"3","companyTruncated":"Synaffix \/ ABL Bio"},{"orgOrder":0,"company":"Synaffix","sponsor":"Sotio","pharmaFlowCategory":"D","amount":"$740.0 million","upfrontCash":"Undisclosed","newsHeadline":"SOTIO Further Expands Next-Generation ADC Platform with License to Synaffix\u2019s ADC Technology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Synaffix","amount2":0.73999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.73999999999999999,"dosageForm":"","sponsorNew":"Synaffix \/ SOTIO","highestDevelopmentStatusID":"3","companyTruncated":"Synaffix \/ SOTIO"},{"orgOrder":0,"company":"Synaffix","sponsor":"Innovent Biologics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Innovent Biologics and Synaffix Expand ADC Collaboration Following Positive Preliminary Clinical Signal from Ongoing Phase 1 Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Licensing Agreement","leadProduct":"IBI-343","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Synaffix","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Synaffix \/ Innovent Biologics","highestDevelopmentStatusID":"6","companyTruncated":"Synaffix \/ Innovent Biologics"}]
Find Clinical Drug Pipeline Developments & Deals by Synaffix
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target